Evidence map›Paper›PMID 30631892›Full record

Observational studyDiabetologia2019

The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.

Stuart J McGurnaghan, Liam Brierley, Thomas M Caparrotta, Paul M McKeigue, Luke A K Blackbourn, Sarah H Wild, Graham P Leese, Rory J McCrimmon, John A McKnight, Ewan R Pearson and 4 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Diabetologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
    Review
  12. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
    Review
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Observational
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stuart J McGurnaghanMRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
Liam BrierleyMRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
Thomas M CaparrottaMRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
Paul M McKeigueUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
Luke A K BlackbournMRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
Sarah H WildUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
Graham P LeeseNinewells Hospital and Medical School, Dundee, DD1 9SY, UK.
Rory J McCrimmonNinewells Hospital and Medical School, Dundee, DD1 9SY, UK.
John A McKnightUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
Ewan R PearsonNinewells Hospital and Medical School, Dundee, DD1 9SY, UK.
John R PetrieInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G12 8TA, UK.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G12 8TA, UK.
Helen M ColhounMRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK. helen.colhoun@igmm.ed.ac.uk.
Scottish Diabetes Research Network Epidemiology Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisDapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is indicated for improving glycaemic control in type 2 diabetes mellitus. Whether its effects on HbA

methodsWe used data from the comprehensive national diabetes register, the Scottish Care Information-Diabetes (SCI-Diabetes) collaboration database, available from 2004 to mid-2016. Data within this database were linked to mortality data from the General Registrar, available from the Information Services Division (ISD) of the National Health Service in Scotland. We calculated crude within-person differences between pre- and post-drug-initiation values of HbA

resultsAmong 8566 people exposed to dapagliflozin over a median of 210 days the crude within-person change in HbA CONCLUSIONS/

interpretationDapagliflozin exposure was associated with reductions in HbA

Indexed as

AgedBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightCardiovascular DiseasesDatabases, FactualDiabetes ComplicationsDiabetes Mellitus, Type 2FemaleGlomerular Filtration RateGlucosidesHumansMaleMiddle AgedPatient SafetyBenzhydryl CompoundsBlood GlucosedapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsDapagliflozinGlycaemic controlType 2 diabetes

Identifiers

PMID30631892

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.